See today's BioWorld
To read the full story, subscribe or sign in.

In $392M deal, C4 and Betta partner in China on preclinical NSCLC drug

May 30, 2023
By Karen Carey
In a deal potentially worth $392 million, C4 Therapeutics Inc. signed with Betta Pharmaceuticals Co. Ltd. to develop and market an orally bioavailable BiDAC degrader for non-small-cell lung cancer (NSCLC).
BioWorld Deals and M&A Cancer China